Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMN4I7P)

Drug Name

GSK3901961 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Cancer/testis antigen 1 (NY-ESO-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CDX-1401	DMCGNJ6	Ovarian cancer	2C73	Phase 2	[2]
CV-9201	DMCPZYT	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[3]
Anti-NY-ESO-1 CAR-T cells	DM26VCZ	Esophageal cancer	2B70	Phase 1/2	[4]
NY-ESO-1 vaccine	DM0EKUQ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
GSK-2241658A	DM5VS7B	Melanoma	2C30	Phase 1	[6]
GSK3845097	DM1UQ4Y	Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]
Melanoma vaccine (ALVAC)	DM3HIQY	Melanoma	2C30	Discontinued in Phase 2	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Clinical pipeline report, company report or official report of GlaxoSmithKline.
2	National Cancer Institute Drug Dictionary (drug id 651880).
3	National Cancer Institute Drug Dictionary (drug id 648549).
4	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
5	Multiepitope CD8+ T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest. 2002 December 15; 110(12): 1813-1822.
6	ClinicalTrials.gov (NCT01213472) Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma. U.S. National Institutes of Health.
7	Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58.